A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 34 450 KRW 2.23% Market Closed
Market Cap: 1.7T KRW

EV/OCF
Enterprise Value to OCF

-22.6
Current
13.3
Median
4.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-22.6
=
Enterprise Value
1.6T KRW
/
Operating Cash Flow
-69.4B KRW
Market Cap EV/OCF
KR
ABL Bio Inc
KOSDAQ:298380
1.7T KRW -22.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -230 191.9
US
Abbvie Inc
NYSE:ABBV
369B USD 22.5
US
Amgen Inc
NASDAQ:AMGN
167.8B USD 18.5
US
Gilead Sciences Inc
NASDAQ:GILD
139.4B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.1B USD -236.6
US
Epizyme Inc
F:EPE
94.1B EUR -489.1
AU
CSL Ltd
ASX:CSL
120.7B AUD 28.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.4B USD 10.8
US
Seagen Inc
F:SGT
39.3B EUR -76.6
NL
argenx SE
XBRU:ARGX
32.1B EUR -121.9
 
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/OCF: 18.9
Negative Multiple: -22.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -230 191.9
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
18.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -489.1
AU
CSL Ltd
ASX:CSL
28.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -76.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -121.9

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.